First Patient Dosed in Phase 3 Trial of Solriamfetol for Major Depressive Disorder with Excessive Daytime Sleepiness
The CLARITY trial utilizes a randomized withdrawal design to assess time to relapse of depressive symptoms in patients with major depressive disorder and excessive daytime sleepiness.
